Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

International Journal of Impotence Research volume 13, pages 282–290 (2001)Cite this article

Abstract

We investigated the potency and the selectivity profile of vardenafil on phosphodiesterase (PDEs) enzymes, its ability to modify cGMP metabolism and cause relaxation of penile smooth muscle and its effect on erections in vivo under conditions of exogenous nitric oxide (NO) stimulation. PDE isozymes were extracted and purified from human platelets (PDE5) or bovine sources (PDEs 1, 2, 3, 4 and 6). The inhibition of these PDEs and of human recombinant PDEs by vardenafil was determined. The ability to potentiate NO-mediated relaxation and influence cGMP levels in human corpus cavernosum strips was measured in vitro, and erection-inducing activity was demonstrated in conscious rabbits after oral administration together with intravenous doses of sodium nitroprusside (SNP). The effects of vardenafil were compared with those of the well-recognized PDE5 inhibitor, sildenafil (values for sildenafil in brackets). Vardenafil specifically inhibited the hydrolysis of cGMP by PDE5 with an IC50 of 0.7 nM (6.6 nM). In contrast, the IC50 of vardenafil for PDE1 was 180 nM; for PDE6, 11 nM; for PDE2, PDE3 and PDE4, more than 1000 nM. Relative to PDE5, the ratios of the IC50 for PDE1 were 257 (60), for PDE6 16 (7.4). Vardenafil significantly enhanced the SNP-induced relaxation of human trabecular smooth muscle at 3 nM (10 nM). Vardenafil also significantly potentiated both ACh-induced and transmural electrical stimulation-induced relaxation of trabecular smooth muscle. The minimum concentration of vardenafil that significantly potentiated SNP-induced cGMP accumulation was 3 nM (30 nM). In vivo studies in rabbits showed that orally administered vardenafil dose-dependently potentiated erectile responses to intravenously administered SNP. The minimal effective dose that significantly potentiated erection was 0.1 mg/kg (1 mg/kg). The selectivity for PDE5, the potentiation of NO-induced relaxation and cGMP accumulation in human trabecular smooth muscle and the ability to enhance NO-induced erection in vivo indicate that vardenafil has the appropriate properties to be a potential compound for the treatment of erectile dysfunction. Vardenafil was more potent and selective than sildenafil on its inhibitory activity on PDE5.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Sáenz de Tejada I et al. Trabecular smooth muscle modulates the capacitor function of the penis. Studies on a rabbit model. Am J Physiol 1991 260, H1590–H1595

    PubMed  Google Scholar 

  2. Virag R, Bouilly P, Frydman D . About arterial risk factors and impotence. Lancet 1985 1, 1109–1110

    Article  CAS  Google Scholar 

  3. Krane RJ, Goldstein I, Sáenz de Tejeda I . Impotence. New Engl J Med 1989 321, 1648–1659

    Article  CAS  Google Scholar 

  4. Azadzoi KM, Goldstein I . Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model. J Urol 1992 147, 1675

    Article  CAS  Google Scholar 

  5. Kim N, Azadzoi KM, Goldstein I, Sáenz de Tejada I . A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991 88, 112–118

    Article  CAS  Google Scholar 

  6. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. New Engl J Med 1992 326, 90–94

    Article  CAS  Google Scholar 

  7. Azadzoi KM et al. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992 147, 220–225

    Article  CAS  Google Scholar 

  8. Burnett AL et al. Nitric oxide: a physiologic mediator of penile erection. Science 1992 257, 401–403

    Article  CAS  Google Scholar 

  9. Holmquist F, Stief CG, Jonas U, Andersson KE . Effects of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol Scand 1991 143, 299–304

    Article  CAS  Google Scholar 

  10. Burnett AL . Role of nitric oxide in the physiology of erection. Biol Reprod 1995 52, 485

    Article  CAS  Google Scholar 

  11. Fawcett L et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 2000 97, 3702–3707

    Article  CAS  Google Scholar 

  12. Beavo JA, Conti M, Heaslip RJ . Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994 46, 399

    CAS  PubMed  Google Scholar 

  13. Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996 8, 47–52

    CAS  PubMed  Google Scholar 

  14. Taher A et al. Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 1997 15, 32–35

    Article  CAS  Google Scholar 

  15. Küthe A et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 2001 165, 280–283

    Article  Google Scholar 

  16. Beavo JA . Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995 75, 725

    Article  CAS  Google Scholar 

  17. Taher A et al. Phosphodiesterase activity in human cavernous tissue and the effect of various selective inhibitors. J Urol 1993 149, (Suppl): 285A (abstract)

    Google Scholar 

  18. Bush PA et al. Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 1992 147, 1650–1655

    Article  CAS  Google Scholar 

  19. Ballard SA et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998 159, 2164–2171

    Article  CAS  Google Scholar 

  20. Trigo-Rocha F, Hsu GL, Donatucci CF, Lue TF . The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. J Urol 1993 149, 872–877

    Article  CAS  Google Scholar 

  21. Carter AJ, Ballard SA, Naylor AM . Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J Urol 1998 160, 242–246

    Article  CAS  Google Scholar 

  22. Bischoff E, Schneider K . A conscious rabbit model is able to demonstrate the efficacy of vardenafil and sildenafil on penile erection. Int J Impot Res 2000 12, (Suppl 3): 65

    Google Scholar 

  23. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. New Engl J Med 1998 338, 1397–1404

    Article  CAS  Google Scholar 

  24. Simonsen U et al. Nitric oxide is involved in the inhibitory neurotransmission and endothelium-dependent relaxations of human small penile arteries. Clin Sci 1997 92, 269–275

    Article  CAS  Google Scholar 

  25. Naganuma H, Egashira T, Fujii J . Neuroleptics induce penile erection in the rabbit. Clin Exp Pharmacol Physiol 1993 20, 177–183

    Article  CAS  Google Scholar 

  26. Eardley I . The role of phosphodiesterase inhibitors in impotence. Exp Opin Invest Drugs 1997 6, 1803–1810

    Article  CAS  Google Scholar 

  27. Sáenz del Tejada I et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. New Engl J Med 1989 320, 1025–1030

    Article  Google Scholar 

  28. Azadzoi KM, Sáenz de Tejada I . Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1990 146, 238

    Article  Google Scholar 

  29. Sachse R, Rohde G . Safety tolerability and pharmacokinetics of multiple dose treatment with the new PDE5-inhibitors BAY 39-9456 (abstract). Eur Urol 2000 37, (Suppl 2): 81

    Article  Google Scholar 

  30. Klotz T et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a Rigiscan™ and pharmacokinetic study. World J Urol 2001 19, 32–39

    Article  CAS  Google Scholar 

  31. Stark S et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001 40, 181–190

    Article  CAS  Google Scholar 

  32. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001 13, 192–199

    Article  CAS  Google Scholar 

  33. Porst H et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function irrespective of the baseline severity and etiology of ED or age of patient (abstract). Eur Urol 2001 38, (Suppl 5): 17

    Google Scholar 

  34. Bischoff E et al. The oral efficacy of vardenafil hydrochloride for inducing penile erections in a conscious rabbit model. J Urol 2001 165, 1316–1318

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fundación para la Investigación y el Desarrollo en Andrología, Madrid, Spain

    I Saenz de Tejada, J Angulo, I Moncada, A Allona & E Lledó

  2. Department Investigación, Hosp Ramón y Cajal, Madrid, Spain

    I Saenz de Tejada, J Angulo, P Cuevas, A Fernández & A Allona

  3. Institut für Biologische Informationsverarbeitung, Forschungszentrum Jülich, Germany

    HG Körschen

  4. BAYER AG Pharmaceutical Business Group, Wuppertal, Germany

    U Niewöhner, H Haning, E Pages & E Bischoff

Authors
  1. I Saenz de Tejada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Angulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Cuevas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Moncada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Allona
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Lledó
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. HG Körschen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. U Niewöhner
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H Haning
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. E Pages
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Saenz de Tejada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saenz de Tejada, I., Angulo, J., Cuevas, P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 13, 282–290 (2001). https://doi.org/10.1038/sj.ijir.3900726

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900726

Keywords

This article is cited by

Search

Advanced search

Quick links